Your browser doesn't support javascript.
loading
Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.
Cesana, Clara; Nosari, Anna Maria; Klersy, Catherine; Miqueleiz, Sara; Rossi, Valentina; Ferrando, Paola; Valentini, Marina; Barbarano, Luciana; Morra, Enrica.
Afiliación
  • Cesana C; Dept.. of Hematology, Bone Marrow Transplantation Center, Niguarda Cà Granda Hospital, Milan, Italy.
Haematologica ; 88(9): 1022-8, 2003 Sep.
Article en En | MEDLINE | ID: mdl-12969810
ABSTRACT
BACKGROUND AND

OBJECTIVES:

We evaluated bacterial infections (BIs) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD). DESIGN AND

METHODS:

Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI.

RESULTS:

By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and post-treatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p<0.02) and multivariate (p<0.002) analyses. Evaluating only the first 4 months of therapy, characterized by a significantly higher incidence of BI than the later period (p<0.0001), previously untreated disease was significantly correlated with BI risk (p<0.04), while male sex (p=0.06), CII schedule (p=0.07), and profound hypogammaglobulinemia (p=0.1) were associated with a tendency to a higher risk of infection; however, at multivariate analysis the latter two parameters independently predicted BI probability (p<0.015 and p<0.03, respectively) as did previously untreated disease (p<0.025). The high probability of CII-related infection was demonstrated to depend on the frequent development of nosocomial infections. INTERPRETATION AND

CONCLUSIONS:

Patients with profound hypogammaglobulinemia who receive VAD as first line treatment are at a major risk of BI up to the completion of the fourth month of therapy. In this setting hospitalization should be avoided and, if patients require admission, antibacterial prophylaxis with intravenous immunoglobulins could be appropriate and effective.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Infecciones Bacterianas / Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Haematologica Año: 2003 Tipo del documento: Article País de afiliación: Italia
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Infecciones Bacterianas / Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Haematologica Año: 2003 Tipo del documento: Article País de afiliación: Italia